Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-31 @ 2:15 AM
Study NCT ID:
NCT07391761
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-18
First Post:
2025-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate:
* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
* What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
* What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
* What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
* What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
Detailed Description:
This study is seeking participants who:
* have relapsed or refractory multiple myeloma (RRMM),
* have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
* are 18 years or older.
Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.
* have relapsed or refractory multiple myeloma (RRMM),
* have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
* are 18 years or older.
Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: